- Johnson & Johnson (NYSE:JNJ) said that new phase 1b data found that candidate bleximenib demonstrated antileukemic activity.
- The selective menin inhibitor, in combination with Venclexta (venetoclax) and Vidaza (azacitidine), is under investigation for acute myeloid leukemia in individuals with certain genetic